Results 221 to 230 of about 38,621 (286)

Cardiac Myosin Inhibitors (CMIs) and Surgical Referral in Patients with Hypertrophic Cardiomyopathy. [PDF]

J Cardiovasc Dev Dis
Ferraresi B, Nenna A, Jawabra M, Corrado D, Faggiano A, Carugo S, Dominici C, Casali G, Chello M, Lusini M.   +9 more
europepmc   +1 more source

Unlocking the Hemodynamic Signature in Hypertrophic Cardiomyopathy: A Path to Better Risk Stratification. [PDF]

JACC Asia
Yang S.
europepmc   +1 more source

Variable cMyBP-C expression from cell to cell in a MYBPC3^c.927-2 A>G hiPSC-CM model recapitulates HCM patient phenotype. [PDF]

Stem Cell Res Ther
Ivaskevica K, Kowalski K, Piep B, Teske J, Meissner JD, Kosanke M, Radocaj A, Montag J, Zweigerdt R, Kraft T, Konze SA.   +10 more
europepmc   +1 more source

Leveraging Large and Diverse Biobanks to Evaluate Gene-Disease Associations in Hypertrophic Cardiomyopathy. [PDF]

J Pers Med
Dababneh SF, Ong K, Yeung D, Hawkins NM, Krahn A, Laksman Z, Tadros R, Roston TM.   +7 more
europepmc   +1 more source

Prognostic factors for cardiovascular-related mortality in pediatric hypertrophic cardiomyopathy: a retrospective cohort study with survival analysis and X-tile stratification. [PDF]

Front Med (Lausanne)
Li S, Zhang N, Su D, Chen C, Qin S, Ye B, Pang Y.   +6 more
europepmc   +1 more source

Hypertrophic Cardiomyopathy and Risk of Out-of-Hospital Cardiac Arrest.

JAMA Netw Open
Dinesen RB, Rajan D, Torp-Pedersen C, Risum N, Warming PE, Tfelt-Hansen J.   +5 more
europepmc   +1 more source

Advancements and Applications of Artificial Intelligence in Hypertrophic Cardiomyopathy: A Comprehensive Review. [PDF]

Rev Cardiovasc Med
Ma H, Li J, Ta S, Yu L, Ruan F, Liu L.
europepmc   +1 more source

Efficacy and safety of mavacamten in non-obstructive hypertrophic cardiomyopathy: A systematic review and meta-analysis of randomized trials. [PDF]

Int J Cardiol Heart Vasc
Abdullah M, Thalib HI, Tahir MB, Khalid N, Mushtaq A, Afzal MA, Moore MD, Sharma N, Muddassir S, Ayers MP, Albaghdadi M, Aronow WS.   +11 more
europepmc   +1 more source

Mavacamten and atrial fibrillation: assessing the risk through FAERS and meta-analysis. [PDF]

BMC Cardiovasc Disord
Ding L, Liao X, Yang Y, Chen C, Xiao J.
europepmc   +1 more source